Biotech entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention ICOTYDE, the most common co-covered peer. MIMRYLO appears in 1 tracked Biotech story from September 8, 2026. The tracked stories average 2 original sources each.
Last mentioned: 3d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention ICOTYDE, the most common co-covered peer. MIMRYLO appears in 1 tracked Biotech story from September 8, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 2 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MIMRYLO. Shared-story counts are live from our verified record — not editorial picks.
Protagonist's board authorized a $300 million repurchase, backed by $849.5 million in cash and royalty streams from two FDA-approved drugs. For biotech observers, the move marks a shift from cash burn to capital return as partnered products generate milestone and royalty income.
Source: finanznachrichten.de · Seeking Alpha
MIMRYLO is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
